Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature

Trial Profile

Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Therapeutic Use
  • Acronyms NEPTUNES
  • Most Recent Events

    • 28 Jun 2022 The protocol was amended to add a new cohort of patients receiving Nivolumab 3 mg/kg and ipilimumab 1 mg/kg every three weeks for a maximum of 4 doses with a 3 week gap after last combination dose, according to ClinicalTrials.gov record. Accordingly, the patient number was changed to 380.
    • 28 Jun 2022 Planned End Date changed from 1 Jul 2025 to 1 Jun 2027.
    • 28 Jun 2022 Planned primary completion date changed from 1 Apr 2022 to 1 Aug 2022.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top